CNS disorders therapeutic - AMRI/Bristol-Myers Squibb

Drug Profile

CNS disorders therapeutic - AMRI/Bristol-Myers Squibb

Alternative Names: Triple reuptake inhibitor

Latest Information Update: 09 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AMRI
  • Developer AMRI; Bristol-Myers Squibb
  • Class
  • Mechanism of Action Biogenic amine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II CNS disorders

Most Recent Events

  • 09 Sep 2016 CNS disorders therapeutic is still in phase II development for CNS disorders (AMRI pipeline, September 2016)
  • 25 May 2011 Phase-II clinical trials in CNS disorders (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top